Company Overview
---------
Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.
The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 50 countries and regions worldwide, including Asia, Europe, South America. Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy and relevant accessory products.